GBS-NN/NN2 (50 µg of Each Fusion Protein [GBS-NN and GBS-NN2] in Combination With 500 µg Aluminum as Alhydrogel®) Given With and Without the Tdap Vaccine in Healthy Non-pregnant Women 18 to 49 Years of Age

Clinical trial NCT06494475 · UNKNOWN

Trial details

NCT number: NCT06494475
Sponsor: Minervax ApS
Status: UNKNOWN
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Streptococcus Agalactiae Infection

Start date: 2024-12-17
Primary completion: 2025-06-21
Enrollment: 564

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.